Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study

https://www.thelancet.com/collections/haematological-cancer?dgcid=hubspot_update_feature_updatealerts_lanhae&parent=001611&utm_campaign=update-lanhae&utm_medium=email&_hsenc=p2ANqtz--ZsIFTYA1UxsDEVrtRkJv2KHzznCao31pNc5JgEh_GhJnEg32HopC8ha_TouCdurHh3wu-xNDem2a6Ws0eWqmrwSBHWQ&_hsmi=360940077&utm_content=360705662&utm_source=hs_email